JPRN-jRCT2031220089招募中1 期
A Phase Ib/II study of regorafenib and nivolumab plus chemotherapy in patients with unresectable advanced/recurrent gastric/gastroesophageal junction/esophageal adenocarcinoma - REGONIVOCTx
Kawazoe Akihito0 个研究点目标入组 36 人开始时间: 2022年5月25日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 36
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1.Histologically confirmed gastric/ gastroesophageal junction/esophageal adenocarcinoma that is confirmed to be unresectable/recurrent disease
- •2.At least 1 measurable lesion as defined by RECIST guideline version 1.1.
- •3.Age >= 20 years on the day informed consent is obtained
- •4.ECOG Performance status (PS) 0 or 1
- •5.The most recent laboratory value within 14 days prior to enrollment meets all of the following. (Examinations on the same day of the week 2 weeks prior to the day of enrollment may be utilized.)
- •1)Neutrophils >= 1,200/mm^3
- •2)Hemoglobin >= 8.0 g/dL
- •3)Platelets >= 75,000/mm^3
- •4)Total bilirubin <= 1.5 mg/dL
- •5)AST (GOT) <= 100 IU/L
- •If liver metastases are present: <= 200 IU/L
- •6)ALT (GPT) <= 100 IU/L
- •If liver metastases are present: <= 200 IU/L
- •7)Creatinine <= 1.5 mg/dL
- •8)Urine protein: any of the following (if any of the test criteria are met, other tests may not be performed.)
- •(i)Urine protein (dipstick) <= 2+
- •(ii)Urine protein creatinine (UPC) ratio < 3.5
- •(iii)Urine protein <= 3,500 mg for 24-hour collection sample
- •9)PT-INR: <= 1.5 (<= 3.0 if on an anticoagulant)
- •6.No transfusions within 7 days prior to enrollment. (Transfusions on the same day of the week prior to enrollment are allowed)
- •7.Women of childbearing potential must have a negative pregnancy test within 7 days prior to enrollment. Both men and women must agree to use adequate contraception from the time of signing the informed consent form for a period of time (9 months in women and 7 months in men) after the last dose of protocol therapy
- •8.Oral administration is feasible
- •9.Written informed consent to participate in the study has been obtained from the patient themselves
排除标准
- •1.Prior chemotherapy for unresectable advanced/recurrent gastric/ gastroesophageal junction/esophageal adenocarcinoma (Note: Prior neoadjuvant or adjuvant therapy is allowed. However, treatment must have been completed at least 6 months prior to enrollment and progression must have occurred at least 6 months after the completion of the therapy)
- •2.HER2 positive (IHC3+, or IHC2+ and FISH positive)
- •3.Patients with hypertension that is difficult to control (systolic blood pressure >= 160 mmHg or diastolic blood pressure >= 90 mmHg) despite multiple antihypertensive medications
- •4.Patients with a history of acute coronary syndrome (including myocardial infarction and unstable angina), coronary angioplasty, or stent placement within 6 months prior to enrollment
- •5.Patients with a history or evidence of congestive heart failure of Class III or higher according to the New York Heart Association (NYHA) classification
- •6.Confirmed metastases to the central nervous system (Confirmation by brain computed tomography scan or magnetic resonance imaging is required at screening only if metastases to the central nervous system are clinically suspected)
- •7.Active double cancers with intensive treatments and possibly affect continuation of protocol treatment
- •8.Those with serious (needing inpatient care) complications (intestinal paralysis, intestinal obstruction, pulmonary fibrosis, poorly controlled diabetes mellitus, cardiac failure, myocardial infarction, angina pectoris, renal failure, hepatic failure, psychiatric disease, cerebrovascular disorder, ulcers requiring blood transfusions, etc.)
- •9.Those with active hepatitis
- •-HBs antigen positive
- •-HBs antibody or HBc antibody positive and HBV-DNA positive
- •-Active hepatitis C (e.g., qualitative detection of HCV RNA)
- •However, those who are HBs antigen positive may be considered eligible if HBV DNA is <1.3 log IU/mL (<2.1 log copies/mL) after treatment with antiviral drugs, such as nucleoside analogs.
- •10.Confirmed HIV infection
- •11.Patients with concurrent autoimmune disease or a history of chronic or recurrent autoimmune disease. Patients with type 1 diabetes mellitus, hypothyroidism which is manageable by hormone replacement, or skin disorders not requiring systemic treatment (such as vitiligo, psoriasis, or alopecia) are permitted to be enrolled.
- •12.Patients who require treatment with systemic corticosteroids (excluding temporary use for testing or prophylactic administration for allergic reactions, or for reduction of edema associated with radiotherapy), or immunosuppressants, or those treated with any of these therapies within 2 weeks prior to study enrollment
- •13.Patients who fail to use adequate contraception during the study participation and contraception period
- •14.Those unwilling or unable to comply with the protocol
- •15.Those considered by the principal investigator or sub-investigator as ineligible for this investigator-initiated trial
研究者
相似试验
尚未招募
不适用
First-line reogorafenib-nivolumab combination for advanced hepatocellular carcinomaNeoplasmsKCT0004867Asan Medical Center42
招募中
2 期
REGOMUNE : A phase I/II study of Regorafenib plus Avelumab in solid tumors2023-509500-15-00Institut Bergonie827
招募中
1 期
Phase Ib study of the combination of regorafenib with conventional chemotherapy for the treatment of newly diagnosed patients with multimetastatic Ewing sarcoma - REGO-INTER-EWING1ewly diagnosed patients with metastatic (other than lung/pleura metastases only) Ewing sarcomaCTIS2023-503322-39-00Institut Gustave Roussy29
进行中（未招募）
2 期
SARC038: Phase 2 Study of Regorafenib and Nivolumab in OsteosarcomaOsteosarcomaOsteosarcoma in ChildrenOsteosarcoma RecurrentOsteosarcoma MetastaticNCT04803877Sarcoma Alliance for Research through Collaboration48
进行中（未招募）
1 期
A randomized phase II study between regorafenib and continuing biologic treatment to multi treated patients with colorectal cancer.Patient with metastatic colorectal cancerMedDRA version: 19.0Level: LLTClassification code 10010028Term: Colorectal cancer Duke's DSystem Organ Class: 100000004864EUCTR2016-002222-37-DKHerlev og Gentofte Hospital60